Today’s cannabis news is dominated by a sharpening federal posture in the United States, with the Trump administration moving against intoxicating hemp products and the DEA pushing medical operators toward Schedule III compliance just as a major class action lands at the industry’s door. Across the Atlantic, the UK marks a manufacturing first that signals the maturation of its medical cannabis supply chain, while in Virginia advocates make a final push for adult-use sales and Tilray’s beer-led pivot loses its fizz with investors.
The federal government has signalled it intends to use newly asserted authority to clamp down on intoxicating hemp-derived products, opening a fresh regulatory front against a market that has flourished in the grey area created by the 2018 Farm Bill. The move has profound implications for delta-8 THC and other hemp cannabinoid operators, and could redirect consumer demand back toward state-licensed cannabis dispensaries if enforcement bites.
Source: Cannabis Business Times
Industry guidance is hardening around the post-rescheduling reality: medical cannabis operators are being told they must register with the DEA to continue handling product under Schedule III rules. The administrative lift is non-trivial and exposes how rescheduling, far from being a deregulatory win, is layering federal compliance obligations onto businesses that have until now operated entirely under state regimes.
Source: Cannabis Business Times
Several of the largest US cannabis operators are facing legal action over allegations that they have marketed recreational-grade products with therapeutic claims they cannot substantiate. The case threatens to reset the boundary between wellness positioning and medical marketing across the sector, and arrives at a moment when regulators on both sides of the Atlantic are sharpening their focus on health claims.
Source: The Free Press
Curaleaf’s UK arm has begun domestic manufacture of medical cannabis suppositories and pessaries, a first for the British market and a meaningful step in widening administration routes for patients who cannot tolerate inhaled or oral products. The launch underscores how the UK medical sector is moving beyond imported flower and into specialist formulations, with onshore manufacturing capacity becoming a competitive moat.
Source: Business of Cannabis
Reform advocates are pressing Virginia’s governor to sign legislation that would finally activate licensed adult-use sales in the commonwealth, years after possession was legalised. With the bill on the desk and amendment proposals already rejected, the decision will determine whether Virginia closes the gap with neighbouring east coast markets or remains the country’s most prominent example of legal possession without a regulated supply chain.
Source: Filter
The throughline is regulatory gravity: federal action on hemp, DEA registration for medical operators, and a major lawsuit on therapeutic claims all point to a sector being pulled into tighter compliance discipline, even as the UK quietly demonstrates what a maturing medical supply chain looks like. Watch Virginia’s signing decision and the next round of DEA guidance for the cleanest signals on where US policy lands next.
Stay up to date with all the latest on the Cannabis News Hub.
The post Cannabis News Today — Wednesday 6 May 2026: Federal Pressure Mounts as UK Hits Medical Manufacturing Milestone appeared first on Business of Cannabis.
Continue reading...
Trump Administration Claims ‘New Legal Authority’ to Dismantle Hemp Products
The federal government has signalled it intends to use newly asserted authority to clamp down on intoxicating hemp-derived products, opening a fresh regulatory front against a market that has flourished in the grey area created by the 2018 Farm Bill. The move has profound implications for delta-8 THC and other hemp cannabinoid operators, and could redirect consumer demand back toward state-licensed cannabis dispensaries if enforcement bites.
Source: Cannabis Business Times
Medical Cannabis Businesses ‘Need to Register’ With DEA for Schedule III Compliance
Industry guidance is hardening around the post-rescheduling reality: medical cannabis operators are being told they must register with the DEA to continue handling product under Schedule III rules. The administrative lift is non-trivial and exposes how rescheduling, far from being a deregulatory win, is layering federal compliance obligations onto businesses that have until now operated entirely under state regimes.
Source: Cannabis Business Times
Cannabis Giants Sued for Marketing Cannabis as Medicine
Several of the largest US cannabis operators are facing legal action over allegations that they have marketed recreational-grade products with therapeutic claims they cannot substantiate. The case threatens to reset the boundary between wellness positioning and medical marketing across the sector, and arrives at a moment when regulators on both sides of the Atlantic are sharpening their focus on health claims.
Source: The Free Press
Curaleaf Becomes First UK Manufacturer of Medical Cannabis Suppositories and Pessaries
Curaleaf’s UK arm has begun domestic manufacture of medical cannabis suppositories and pessaries, a first for the British market and a meaningful step in widening administration routes for patients who cannot tolerate inhaled or oral products. The launch underscores how the UK medical sector is moving beyond imported flower and into specialist formulations, with onshore manufacturing capacity becoming a competitive moat.
Source: Business of Cannabis
Virginia Governor Urged to Sign Adult-Use Cannabis Sales Bill
Reform advocates are pressing Virginia’s governor to sign legislation that would finally activate licensed adult-use sales in the commonwealth, years after possession was legalised. With the bill on the desk and amendment proposals already rejected, the decision will determine whether Virginia closes the gap with neighbouring east coast markets or remains the country’s most prominent example of legal possession without a regulated supply chain.
Source: Filter
The throughline is regulatory gravity: federal action on hemp, DEA registration for medical operators, and a major lawsuit on therapeutic claims all point to a sector being pulled into tighter compliance discipline, even as the UK quietly demonstrates what a maturing medical supply chain looks like. Watch Virginia’s signing decision and the next round of DEA guidance for the cleanest signals on where US policy lands next.
Stay up to date with all the latest on the Cannabis News Hub.
The post Cannabis News Today — Wednesday 6 May 2026: Federal Pressure Mounts as UK Hits Medical Manufacturing Milestone appeared first on Business of Cannabis.
Continue reading...
